Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.

DURUSU TANRIÖVER M., Doganay H. L., AKOVA M., Guner H. R., Azap A., AKHAN S., ...More

Lancet (London, England), vol.398, no.10296, pp.213-222, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 398 Issue: 10296
  • Publication Date: 2021
  • Doi Number: 10.1016/s0140-6736(21)01429-x
  • Journal Name: Lancet (London, England)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
  • Page Numbers: pp.213-222
  • Istanbul University Affiliated: Yes


Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.